Clinical Trials

1. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study.

Author
Walz J; Shariat SF; Suardi N; Perrotte P; Lotan Y; Palapattu GS; Gupta A; Bastian PJ; Rogers CG; Vazina A; Amiel GE; Sagalowsky AI; Schoenberg M; Lerner SP; Karakiewicz PI;
Institution
Cancer Prgonosis and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada.
Journal
BJU Int. 2008 Jun;101(11):1356-61.
Abstract URL
Click here to view abstract

2. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.

Author
Dreicer R; Li H; Cooney MM; Wilding G; Roth BJ;
Institution
Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. dreicer@ccf.org
Journal
Cancer. 2008 Jun 15;112(12):2671-5.
Abstract URL
Click here to view abstract

3. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.

Author
Ojea A; Nogueira JL; Solsona E; Flores N; Gomez JM; Molina JR; Chantada V; Camacho JE; Pineiro LM; Rodriguez RH; Isorna S; Blas M; Martinez-Pineiro JA; Madero R; Ojea A; Nogueira JL; Solsona E; Flores N; Gomez JM; Molina JR; Chantada V; Camacho JE; Pineiro LM; Rodriguez RH; Isorna S; Blas M; Martinez-Pineiro JA; Madero R;
Institution
Complejo Hospitalario Universitario de Vigo, Vigo, Spain. aojea@retegal.es
Journal
Eur Urol. 2007 Nov;52(5):1398-406. Epub 2007 Apr 27.
Abstract URL
Click here to view abstract

4. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response van der Heijden AG, Moonen PM, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Barten EJ, Puri R, van Kalken CK, Witjes JA, University Medical Centre Nijmegen, Nijmegen, The Netherlands.

Author
Grossman HB;
Institution
Journal
Urol Oncol. 2007 May-Jun;25(3):271-2.
Abstract URL
Click here to view abstract

5. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.

Author
Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS;
Institution
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Journal
Urology. 2007 Mar;69(3):479-84.
Abstract URL
Click here to view abstract

6. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer.

Author
Naito S; Koga H; Yamaguchi A; Fujimoto N; Hasui Y; Kuramoto H; Iguchi A; Kinukawa N;
Institution
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Journal
J Urol. 2008 Feb;179(2):485-90.
Abstract URL
Click here to view abstract

7. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience.

Author
Perdona S; Autorino R; Damiano R; De Sio M; Morrica B; Gallo L; Silvestro G; Farella A; De Placido S; Di Lorenzo G;
Institution
Comprehensive Urology Unit, National Tumor Institute, G. Pascale Foundation, Naples, Italy.
Journal
Cancer. 2008 Jan 1;112(1):75-83.
Abstract URL
Click here to view abstract

8. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.

Author
Kotwal S; Choudhury A; Johnston C; Paul AB; Whelan P; Kiltie AE;
Institution
Pyrah Department of Urology, St. James's University Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Journal
Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):456-63. Epub 2007 Sep 27.
Abstract URL
Click here to view abstract

9. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.

Author
Lin CC; Hsu CH; Huang CY; Keng HY; Tsai YC; Huang KH; Cheng AL; Pu YS;
Institution
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, ROC.
Journal
Anticancer Drugs. 2007 Apr;18(4):487-91.
Abstract URL
Click here to view abstract

10. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.

Author
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS;
Institution
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Journal
J Urol. 2007 Jan;177(1):84-9; discussion 89.
Abstract URL
Click here to view abstract

11. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.

Author
Dumez H; Martens M; Selleslach J; Guetens G; De Boeck G; Aerts R; De Bruijn EA; Maes RA; van Oosterom AT;
Institution
Department of General Medical Oncology, UZ Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. herlinde.dumez@uz.kuleuven.be
Journal
Anticancer Drugs. 2007 Feb;18(2):211-8.
Abstract URL
Click here to view abstract

12. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.

Author
Galsky MD; Iasonos A; Mironov S; Scattergood J; Boyle MG; Bajorin DF;
Institution
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. matthew.galsky@usoncology.com
Journal
Cancer. 2007 Feb 1;109(3):549-55.
Abstract URL
Click here to view abstract

13. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.

Author
Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI;
Institution
The Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Journal
Clin Cancer Res. 2008 Mar 1;14(5):1510-8.
Abstract URL
Click here to view abstract